Insiders Verve Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
6.01 ^USD	-5.50%		-6.24%	-56.89%

05-08	Verve Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102	CI

Verve Therapeutics Appoints Frederick Fiedorek as Chief Medical Officer	23-09-18	MT
Verve Therapeutics, Inc. Announces Executive Changes	23-09-18	CI
Insider Sell: Verve Therapeutics	22-11-09	MT
Insider Sell: Verve Therapeutics	22-11-04	MT
Insider Sell: Verve Therapeutics	22-11-03	MT
Insider Sell: Verve Therapeutics	22-11-01	MT
Insider Sell: Verve Therapeutics	22-10-05	MT
Insider Sell: Verve Therapeutics	22-09-27	MT
ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate	22-08-22	PU
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress	22-08-22	GL
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress	22-08-22	AQ
Insider Sell: Verve Therapeutics	22-08-11	MT
Verve Therapeutics, Inc. Announces Board and Committee Changes	22-08-09	CI
ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate	22-07-31	PU
Insider Sell: Verve Therapeutics	22-07-22	MT
Insider Sell: Verve Therapeutics	22-07-21	MT
Insider Sell: Verve Therapeutics	22-07-15	MT
Verve Therapeutics Appoints Alexander G. "Bo" Cumbo, to Its Board of Directors	22-06-13	CI
Insider Sell: Verve Therapeutics	21-12-29	MT
Insider Sell: Verve Therapeutics	21-12-28	MT

No results for this search